TN-LP-BUILDING-PRODUCTS
LP ® SolidStart ® I-Joist Product Family Earns CE Approval, European Technical Approval
LP Building Products (NYSE: LPX) has announced the addition of a full range of LP® SolidStart® I-Joists (ETA-12/0480; CE: 0679-CPD-0840, 0679-CPD -0839) to its engineered wood product offerings. One of the broadest ranges available in the European market today, it includes five joist series from the lightweight and economical LPI 18 series—ideal where deep depth product is required to meet the increased insulation demand of the new Passive House designs—to the span buster LPI 52 series, which is available in depths up to 610mm.
The three most popular series—the battle joist energy-efficient LPI 18, the mid-range LPI 20 and the problem solver LPI 42—are now available in metric depths of 225mm, 240mm, 300mm, 360mm and 400mm. All other series and depths can be special ordered between 200mm and 610mm deep. The products are available in two standard flange widths, 63mm and 89mm, to provide for reduced blocking lengths making for easier detailing and cutting as well as simpler on-site installation.
In addition to the new metric depths, LP is the first company to supply a fit-for-purpose 225mm depth, engineered to match UK brick and block coursing and standard EU Glulam depth. Product lengths are available in standard 300mm or 600mm increments up to 12.0m with 13.5m lengths available on special order.
All LP SolidStart I-Joists come standard with a specialty grade oriented strand board (OSB) web, including a pre-stamped 38mm knockout hole for services and venting at 300mm centres. All of the flanges are made from an enhanced proprietary-graded, machine stress-graded timber, which is tension tested before assembly. The entire LP SolidStart I-Joist family is backed by a lifetime limited warranty.
LP Building Products now has ETA or CE approval on the following growing family of products, with more to follow later this year:
-
LP®
SmartSide®
Trim & Siding
- Structural Panels
- Lap Siding
- Trim
-
CE Plywood
- Square Edge
- T&G
-
LP SolidStart LVL (DF or SYP) (CE: 0679-CPD -0816, 0679-CPD -0817)
- LVL-Q Lite (1.3E)
- LVL-S Lite (1.9E)
- LVL-S (2.0E)
- LVL-S Plus (2.1E)
-
LP SolidStart I-Joists (CE: 0679-CPD-0840, 0679-CPD -0839)
- LPI 18 (63mm)
- LPI 20 (63mm)
- LPI 32 (63mm)
- LPI 42 (89mm)
- LPI 52 (89mm)
LP SolidStart I-Joists are distributed through a growing network of wholesale distributors along with their stocking dealers, timber frame and truss manufacturer customers.
- Falcon Panel Products Limited – UK
- MBM Forest Products Limited – UK
- SpanoGroup – Belgium
- van Hoorebeke Timber – Belgium
- Wyder Engineered Timber Systems Limited – UK
LP is now targeting new wholesale distributors in France and Germany.
About LP Building Products
Louisiana-Pacific Corporation is a leading manufacturer of quality engineered wood building materials including OSB, structural framing products, and exterior siding for use in residential, industrial and light commercial construction. From manufacturing facilities in the U.S., Canada, Chile and Brazil, LP products are sold to builders and homeowners through building materials distributors and dealers and retail home centers. Founded in 1973, LP is headquartered in Nashville, Tennessee, and traded on the New York Stock Exchange under LPX. For more information, visit LPCorp.com/UK or contact us at IntlSales@LPCorp.com .
Contact:
GS&F
Angie VanTassell, +1-615-385-1100
avantassell@gsandf.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum